Loading...
XNASIRMD
Market cap728mUSD
Jan 14, Last price  
57.52USD
1D
1.79%
1Q
11.58%
Jan 2017
418.20%
IPO
539.11%
Name

IRadimed Corp

Chart & Performance

D1W1MN
XNAS:IRMD chart
P/E
42.40
P/S
11.12
EPS
1.36
Div Yield, %
1.81%
Shrs. gr., 5y
0.99%
Rev. gr., 5y
16.59%
Revenues
66m
+23.00%
7,685,06111,340,09715,653,05731,593,72032,496,54823,081,59230,438,98338,517,14131,717,37241,814,58153,303,14565,562,296
Net income
17m
+34.02%
966,0851,936,8902,050,3667,529,9207,214,545499,7646,303,4509,630,9591,369,0019,325,47112,828,48717,192,776
CFO
13m
+34.08%
1,509,1561,474,3972,585,7207,649,3309,406,3203,415,9187,376,01510,232,7335,817,49611,258,15610,042,71113,465,012
Dividend
Aug 20, 20240.15 USD/sh
Earnings
Feb 06, 2025

Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
URL
http://www.iradimed.com/
IPO date
Jul 16, 2014
Employees
123
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
65,562
23.00%
53,303
27.48%
Cost of revenue
45,527
37,676
Unusual Expense (Income)
NOPBT
20,035
15,628
NOPBT Margin
30.56%
29.32%
Operating Taxes
4,545
3,353
Tax Rate
22.69%
21.46%
NOPAT
15,490
12,274
Net income
17,193
34.02%
12,828
37.56%
Dividends
(13,223)
(12,559)
Dividend yield
2.19%
3.51%
Proceeds from repurchase of equity
(434)
(147)
BB yield
0.07%
0.04%
Debt
Debt current
856
293
Long-term debt
5,273
4,117
Deferred revenue
2,794
1,375
Other long-term liabilities
(1,615)
1,375
Net debt
(43,633)
(53,550)
Cash flow
Cash from operating activities
13,465
10,043
CAPEX
(7,441)
(1,875)
Cash from investing activities
(8,007)
(1,375)
Cash from financing activities
(13,657)
(12,706)
FCF
6,452
7,302
Balance
Cash
49,762
57,961
Long term investments
Excess cash
46,484
55,296
Stockholders' equity
43,259
47,266
Invested Capital
33,425
31,240
ROIC
47.91%
39.53%
ROCE
26.13%
20.26%
EV
Common stock shares outstanding
12,723
12,636
Price
47.47
67.80%
28.29
-38.78%
Market cap
603,938
68.95%
357,472
-38.56%
EV
560,305
303,921
EBITDA
20,801
16,298
EV/EBITDA
26.94
18.65
Interest
582
Interest/NOPBT
3.72%